FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April, 2025 Commission File Number: 001-12518 Banco Santander, S.A. (Exact name of registrant as specified in its charter) Ciudad Grupo Santander 28660 Boadilla del Monte (Madrid) Spain (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F ...

Core Points - Sanofi has expanded its partnership with McLaren Racing and United Autosports to raise awareness about meningitis during the 24 Hours of Le Mans race [2][3] - The Meningitis Flag will be prominently displayed on the 59 McLaren car and worn by team drivers, aiming to increase global awareness of meningitis [2][3][5] - The initiative highlights the importance of vaccination, early detection, and symptom awareness in combating meningitis, especially in light of rising cases post-COVID-19 pandemic [3][5] Company and Industry Insights - Every 15 seconds, someone contracts meningitis, with bacterial meningitis being particularly severe and potentially fatal within 24 hours [3] - The partnership between Sanofi and McLaren Racing began in 2022, leveraging McLaren's digital and analytical expertise to enhance Sanofi's manufacturing operations [8] - The Le Mans race attracts over 300,000 attendees and has more than 140 million viewers, providing a significant platform for raising awareness [8]

Core Insights - The company reported a Q1 sales growth of 9.7% at constant exchange rates (CER) and a business EPS of €1.79, indicating a strong start to 2025 [1][3][8] Sales Performance - Pharma launches generated sales of €0.8 billion, reflecting a 43.8% increase, primarily driven by ALTUVIIIO [6] - Dupixent sales reached €3.5 billion, up 20.3%, while vaccine sales amounted to €1.3 billion, up 11.4% due to favorable phasing of Beyfortus [6] - Total IFRS net sales were reported at €9,895 million, representing a 10.8% increase [8] Financial Metrics - Business EPS increased by 17.0% reported and 15.7% at CER, reaching €1.79 [6][8] - IFRS net income rose by 65.2% to €1,872 million, with IFRS EPS reported at €1.52, up 67.0% [8] - Free cash flow was reported at €1,029 million [8] Pipeline and Approvals - The company achieved six regulatory approvals across various therapeutic areas, including immunology, rare diseases, and oncology [6][5] - Significant progress was noted in the pipeline, with new data from mid-stage studies unlocking late-stage studies in asthma and skin diseases [6][5] Capital Allocation and Strategy - The company confirmed its capital allocation strategy, including a share buyback program of €5 billion, with 72% already repurchased [7][4] - The anticipated closing of the sale of a controlling stake in Opella is expected in Q2 [7] Future Outlook - Sales are projected to grow by a mid-to-high single-digit percentage at CER in 2025, with business EPS expected to increase at a low double-digit percentage at CER before share buyback [7]

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved Paris and Tarrytown, NY, April 18, 2 ...

Core Insights - Sanofi has made significant advancements in its respiratory pipeline, particularly with the drug amlitelimab for asthma, showing promising preliminary phase 2 results [1][2][3] Group 1: Amlitelimab in Asthma - The TIDE-Asthma phase 2 study revealed that while the primary endpoint of annualized exacerbation rate at week 48 was not met at the highest dose, there were nominally significant reductions in asthma exacerbations at medium and low doses [2] - Amlitelimab demonstrated a more than 70% reduction in exacerbations in a biomarker-defined patient subgroup, indicating its potential to address unmet needs in asthma treatment [2][3] - The treatment regimen involved administration every four weeks for the first 24 weeks, followed by every 12 weeks, supporting a quarterly maintenance dosing schedule [3][11] Group 2: Future Clinical Studies - A phase 3 program for amlitelimab is currently being planned, with full results from the TIDE-Asthma study to be presented at an upcoming medical meeting [2][4] - Sanofi is also exploring lunsekimig in chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis, with phase 2 study results anticipated in 2026 [5][6] - Itepekimab is expanding its clinical studies into chronic rhinosinusitis and bronchiectasis, with phase 3 readouts expected in H2 2025 [7][9][8] Group 3: Mechanism of Action and Safety Profile - Amlitelimab operates through a unique non-depleting mechanism targeting OX40-Ligand, aiming to restore immune balance with infrequent dosing [3][10] - The safety profile of amlitelimab was consistent with previous studies, with no new safety signals identified, and treatment emergent adverse effects were similar between amlitelimab and placebo groups [3][11]

Investors might want to bet on Banco Santander (SAN) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individ ...

Core Insights - Tolebrutinib has shown positive results in delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), a condition currently lacking approved treatment options [1][6] - The HERCULES phase 3 study results were published in the New England Journal of Medicine (NEJM) and presented at major neurology conferences, indicating a significant advancement in multiple sclerosis treatment [1][2] Tolebrutinib Efficacy - In the HERCULES study, tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo, with a hazard ratio of 0.69 and a p-value of 0.003 [3][6] - The GEMINI 1 and 2 studies did not demonstrate superiority in reducing annualized relapse rate (ARR) compared to teriflunomide, with ARR of 0.13 for tolebrutinib and 0.12 for teriflunomide in GEMINI 1, and 0.11 for both groups in GEMINI 2 [4][17] Safety Profile - Tolebrutinib was generally well-tolerated, with liver enzyme elevations observed in 4.0% of participants compared to 1.6% in the placebo group in the HERCULES study [5][7] - A small proportion (0.5%) of participants experienced significant ALT increases (>20xULN), all occurring within the first 90 days of treatment [5][7] Regulatory Status - Tolebrutinib is under priority review by the US FDA with a target action date of September 28, 2025, and a regulatory submission is also under review in the EU [6][8] - The drug has previously received breakthrough therapy designation from the FDA based on positive phase 3 study results [12] Mechanism of Action - Tolebrutinib is a Bruton's tyrosine kinase (BTK) inhibitor designed to target neuroinflammation behind the blood-brain barrier, addressing the underlying pathology of progressive multiple sclerosis [11][13] - This mechanism allows it to modulate both B-lymphocytes and disease-associated microglia, potentially transforming the treatment landscape for multiple sclerosis [11][13]

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,467,152,142Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under nu ...

Core Insights - Investors are considering Banco Santander (SAN) and National Australia Bank Ltd. (NABZY) for potential value opportunities in the Banks - Foreign sector [1] Valuation Metrics - Banco Santander has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision activity compared to National Australia Bank Ltd., which has a Zacks Rank of 3 (Hold) [3] - SAN's forward P/E ratio is 7.72, significantly lower than NABZY's forward P/E of 14.41, suggesting SAN may be undervalued [5] - The PEG ratio for SAN is 0.81, while NABZY's PEG ratio is 7.67, indicating SAN's expected earnings growth is more favorable [5] - SAN's P/B ratio is 0.93, compared to NABZY's P/B of 1.57, further supporting SAN's valuation attractiveness [6] Value Grades - Based on various valuation metrics, SAN holds a Value grade of A, while NABZY has a Value grade of D, indicating SAN is perceived as a better value investment [6][7]

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. These figures are just a handful of the metrics value investors tend to look at, but they help show that Banco Santander is likely being undervalued right now. Considering this, as well as the strength of its ear ...